Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ivax Confident On Flonase Generic In 2004, Despite Bioequivalence Petitions

This article was originally published in The Tan Sheet

Executive Summary

Ivax expects approval for a generic version of GlaxoSmithKline's nasal steroid Flonase (fluticasone) sometime this year

You may also be interested in...



Glaxo Defends Flonase From Generics With Manufacturing Spec Petition

GlaxoSmithKline is attempting to impede generic competition for itsFlonase nasal steroid with the filing of the second citizen petition this year related to the product

Glaxo Defends Flonase From Generics With Manufacturing Spec Petition

GlaxoSmithKline is attempting to impede generic competition for itsFlonase nasal steroid with the filing of the second citizen petition this year related to the product

Glaxo Defends Flonase From Generics With Manufacturing Spec Petition

GlaxoSmithKline is attempting to impede generic competition for itsFlonase nasal steroid with the filing of the second citizen petition this year related to the product

Topics

UsernamePublicRestriction

Register

OM017181

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel